This article discusses a study being conducted on an extended family in Colombia aimed at evaluating the ability of crenezumab, a drug created by pharmaceutical company Genentech, to prevent the buildup of amyloid proteins in the brain for the purpose of preventing early-onset Alzheimer's disease.
© 2001-2024 Fundación Dialnet · Todos los derechos reservados